This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:2182-2183.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Istanbul—An experimental immunity-enhancing drug administered as a topical gel shows promise in substantially delaying onset of recurrent genital herpes lesions, researchers reported here at the 11th European Congress of Clinical Microbiology and Infectious Diseases.

"One episodic treatment seems to act like a vaccination and prolong the time to the next recurrence," explained Spotswood Spruance, MD, at a symposium sponsored by St Paul, Minn–based 3M Pharmaceuticals. If the findings are confirmed in large-scale studies, the new agent, resiquimod, would provide an alternative to current suppressive therapy for genital herpes, said Spruance, of the University of Utah School of Medicine in Salt Lake City.

Currently approved treatment for recurrent genital herpes comprises a trio of systemic antiviral medications: the nucleoside analogs acyclovir, famciclovir, and valacyclovir.

These drugs can decrease the duration of viral shedding and time to healing of lesions when patients take them at onset of symptoms. . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?